NCT01711528View on ClinicalTrials.gov

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 19, 2012

Primary Completion Date

November 22, 2016

Study Completion Date

November 22, 2016

Conditions
Recurrent Plasma Cell Myeloma
Interventions
DRUG

Bortezomib

Given SC

DRUG

Dexamethasone

Given PO

DRUG

Dinaciclib

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (6)

23298

Virginia Commonwealth University/Massey Cancer Center, Richmond

53792

University of Wisconsin Hospital and Clinics, Madison

54494

Aspirus UW Cancer Center, Wisconsin Rapids

55905

Mayo Clinic, Rochester

77030

M D Anderson Cancer Center, Houston

85259

Mayo Clinic in Arizona, Scottsdale

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01711528 - Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | Biotech Hunter | Biotech Hunter